175 related articles for article (PubMed ID: 17408408)
1. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
Agnelli G; Haas S; Ginsberg JS; Krueger KA; Dmitrienko A; Brandt JT
J Thromb Haemost; 2007 Apr; 5(4):746-53. PubMed ID: 17408408
[TBL] [Abstract][Full Text] [Related]
2. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
[TBL] [Abstract][Full Text] [Related]
3. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
[TBL] [Abstract][Full Text] [Related]
4. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
[TBL] [Abstract][Full Text] [Related]
6. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Eriksson BI; Borris L; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Kälebo P;
J Thromb Haemost; 2006 Jan; 4(1):121-8. PubMed ID: 16409461
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
9. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial.
Navarro-Quilis A; Castellet E; Rocha E; Paz-Jiménez J; Planès A;
J Thromb Haemost; 2003 Mar; 1(3):425-32. PubMed ID: 12871445
[TBL] [Abstract][Full Text] [Related]
11. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
[TBL] [Abstract][Full Text] [Related]
12. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Eriksson BI; Turpie AG; Lassen MR; Prins MH; Agnelli G; Kälebo P; Wetherill G; Wilpshaar JW; Meems L;
J Thromb Haemost; 2010 Apr; 8(4):714-21. PubMed ID: 20088935
[TBL] [Abstract][Full Text] [Related]
13. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
15. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Eriksson BI; Ogren M; Eriksson UG; Kälebo P; Ahnfelt L; Björkström S; Sjöstedt A; Folestad A; Arfwidsson AC; Elvander CS; Frison L
Thromb Res; 2002 Mar; 105(5):371-8. PubMed ID: 12062537
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
18. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
19. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
Fuji T; Ochi T; Niwa S; Fujita S
J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
[TBL] [Abstract][Full Text] [Related]
20. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.
Quinlan DJ; Eikelboom JW; Dahl OE; Eriksson BI; Sidhu PS; Hirsh J
J Thromb Haemost; 2007 Jul; 5(7):1438-43. PubMed ID: 17425687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
